The fourth quarter performance is in line with the company’s expectations and lays the foundation for a stronger 2026, CEO Kevin Hammons said.
Related Posts
CMS launching payment model to boost access to GLP-1s in Medicaid, Part D
The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies.
Breakthrough Therapies Aren’t Enough: What Neurology Needs Now
Neurology is at a turning point. After decades of limited progress, new disease-modifying treatments (DMTs) for neurodegenerative conditions like Alzheimer’s and many others are finally […]
URAC starts AI accreditation for users and developers of health AI
The accreditation body will vet the risk management and business practices of healthcare organizations using or developing AI.